Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 3/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ncx-4016 SCHEMBL29546681 | 1.00 | PTGS2 (0.57) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Ncx-4016 SCHEMBL29813476 | 1.00 | PTGS2 (0.57) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL5605673 | 0.89 | PTGS2 (0.60) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL20871763 | 0.89 | PTGS2 (0.43) | PTGS2HSD17B10CYP1A2CYP2C9MAPT | |
| SCHEMBL4328024 | 0.87 | PTGS2 (0.54) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL4138781 | 0.87 | PTGS2 (0.64) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL29454034 | 0.87 | PTGS2 (0.64) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL20871352 | 0.86 | PTGS2 (0.41) | PTGS2HSD17B10CYP1A2CYP2C9MAPT | |
| SCHEMBL4959789 | 0.85 | PTGS2 (0.49) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL12268187 | 0.85 | KMT2A (0.49) | PTGS2HSD17B10LMNACYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | claimed |
| WO-2025230907-A1 | A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-06 | — | — | WO | claimed |
| EP-3463434-B1 | IMMUNOTHERAPY FOR CANCER | EXCOSO A S (CZ) | 2024-12-25 | — | — | EP | claimed |
| WO-2024221005-A2 | METHODS FOR INHIBITING RESISTANCE TO IMMUNE BLOCKADE INHIBITOR THERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-10-24 | — | — | WO | claimed |
| EP-4426274-A1 | NITRIC OXIDE DONORS FOR USE IN SURGICAL RECOVERY | Baxter International Inc. (US) | 2024-09-11 | — | — | EP | claimed |
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | KEEFER, Edward (US) | 2024-08-29 | — | — | US | claimed |
| US-12029755-B2 | Carbon monoxide-based therapies and implantable devices for the treatment of vascular disease | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-07-09 | — | — | US | claimed |
| US-11969522-B2 | Use of immune modulators to improve nerve regeneration | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-30 | — | — | US | claimed |
| US-11850230-B2 | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | ILAB (KR) | 2023-12-26 | — | — | US | claimed |
| WO-2023081681-A1 | NITRIC OXIDE DONORS FOR USE IN SURGICAL RECOVERY | BAXTER INTERNATIONAL INC. (US) | 2023-05-11 | — | — | WO | claimed |
| WO-2007054451-A1 | USE OF COMBINATIONS OF NITRIC OXIDE-RELEASING ASPIRIN AND ASPIRIN FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | NICOX S.A. (FR) | 2007-05-18 | — | — | WO | claimed |
| US-20060052437-A1 | Combination of an hmg-coa reductase inhibitor and a nitrate ester | SCARAMUZZINO GIOVANNI | 2006-03-09 | — | — | US | claimed |
| EP-1147074-B1 | SYNTHESIS METHOD OF NITROXYMETHYLPHENYL ESTERS OF ASPIRIN DERIVATIVES | NICOX SA (FR) | 2005-03-23 | — | — | EP | claimed |
| EP-1505986-A1 | COMBINATION OF AN HMG-CoA REDUCTASE INHIBITOR AND A NITRATE ESTER | Scaramuzzino, Giovanni (IT) | 2005-02-16 | — | — | EP | claimed |
| EP-1492543-A1 | DRUGS FOR THE ARTHRITIS TREATMENT | Nicox S.A. (FR) | 2005-01-05 | — | — | EP | claimed |
| US-20040023933-A1 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2004-02-05 | — | — | US | claimed |
| WO-2003094923-A1 | COMBINATION OF AN HMG-CoA REDUCTASE INHIBITOR AND A NITRATE ESTER | SCARAMUZZINO GIOVANNI (IT) | 2003-11-20 | — | — | WO | claimed |
| WO-2003084550-A1 | DRUGS FOR THE ARTHRITIS TREATMENT | NICOX S.A. (FR) | 2003-10-16 | — | — | WO | claimed |
| EP-1339665-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | Nicox S.A. (FR) | 2003-09-03 | — | — | EP | claimed |
| WO-2002030866-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850230-B2 | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | TNF, NFKBIA, TRAF6 | PTGS2 325/4885HSD17B10 735/4885KDM4E 2226/4885 |
| US-12029755-B2 | Carbon monoxide-based therapies and implantable devices for the treatment of vascular disease | MB, VCAM1, NOS2 | PTGS2 66/4885HSD17B10 2862/4885KDM4E 2284/4885 |
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | CXCR3, CXCL12, CXCR4 | PTGS2 157/4885HSD17B10 4292/4885KDM4E 3304/4885 |
| US-20040023933-A1 | Nitroderivatives as drugs for diseases having an inflammatory basis | TPMT, NOX1, CBR1 | PTGS2 64/4885HSD17B10 606/4885KDM4E 4320/4885 |
| US-20060052437-A1 | Combination of an hmg-coa reductase inhibitor and a nitrate ester | HMGCR, NNT, VKORC1 | PTGS2 52/4885HSD17B10 92/4885KDM4E 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.